Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Johnson

Showing results (141-150 of 152) with videos related to

Pageof 16
Sort By:
Molecular Cell|October 16, 2025
PALB2 and 53BP1 govern post-resection homologous recombination DNA repairYifan Wang, Yan Coulombe, Wei-Ting Yueh, et al.
Molecular Cell|August 1, 2025
PALB2 and 53BP1 govern post-resection homologous recombination DNA repairYifan Wang, Yan Coulombe, Wei-Ting Yueh, et al.
Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
Molecular Cancer Therapeutics|December 8, 2023
4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative StressMarissa L Calbert, Gurushankar Chandramouly, Clare M Adams, et al.
GMS Health Innovation and Technologies|October 31, 2022
The time is now: Achieving FH paediatric screening across Europe - The Prague DeclarationNicole Bedlington, Marianne Abifadel, Birgit Beger, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Cassandra J Vandenberg, et al.
Molecular Cancer|August 5, 2024
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Yifan Wang, et al.
Atherosclerosis|May 8, 2025
The Brussels International Declaration on Lipoprotein(a) Testing and ManagementFlorian Kronenberg, Nicola Bedlington, Zanfina Ademi, et al.
Cancer Research|July 3, 2021
<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP InhibitorsSilvia Maifrede, Bac Viet Le, Margaret Nieborowska-Skorska, et al.
Pageof 16

Showing results (141-150 of 152) with videos related to

Sort By:
Pageof 16
Molecular Cell|October 16, 2025
PALB2 and 53BP1 govern post-resection homologous recombination DNA repairYifan Wang, Yan Coulombe, Wei-Ting Yueh, et al.
Molecular Cell|August 1, 2025
PALB2 and 53BP1 govern post-resection homologous recombination DNA repairYifan Wang, Yan Coulombe, Wei-Ting Yueh, et al.
Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
Molecular Cancer Therapeutics|December 8, 2023
4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative StressMarissa L Calbert, Gurushankar Chandramouly, Clare M Adams, et al.
GMS Health Innovation and Technologies|October 31, 2022
The time is now: Achieving FH paediatric screening across Europe - The Prague DeclarationNicole Bedlington, Marianne Abifadel, Birgit Beger, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Cassandra J Vandenberg, et al.
Molecular Cancer|August 5, 2024
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nesic, John J Krais, Yifan Wang, et al.
Atherosclerosis|May 8, 2025
The Brussels International Declaration on Lipoprotein(a) Testing and ManagementFlorian Kronenberg, Nicola Bedlington, Zanfina Ademi, et al.
Cancer Research|July 3, 2021
<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP InhibitorsSilvia Maifrede, Bac Viet Le, Margaret Nieborowska-Skorska, et al.
Pageof 16